Antimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Curr Pharm Des. 2022;28(38):3105-3113. doi: 10.2174/1381612828666220921150037.
The conventional treatment is faced with limitations in treating solid tumors due to their specific pathophysiology. Several novel therapeutics have been introduced in recent decades to treat solid tumors. Among these new methods, tumor therapy using bacterial products like bacteriocins and peptides has been of great interest due to their unique characteristics and advantages of them in comparison to the conventional treatment, including that they can precisely target tumor cells, selective toxicity for tumor cells, low side effect on normal cells, toxicity activity for MDR cancer cells, used as the target delivery vehicles and enhancing drug delivery. Moreover, their small size and low molecular weight have made them easy to synthesize and modify. Furthermore, in recent years, genetic engineering has expanded the therapeutic ability of peptides to treat solid tumors, which results in overcoming the peptide drawbacks. The present review mainly focuses on the new advances in applying bacterial peptides and bacteriocins in treating human solid tumors.
传统疗法在治疗实体瘤方面面临局限，因为它们具有特定的病理生理学特征。近几十年来，已经引入了几种新的治疗方法来治疗实体瘤。在这些新方法中，由于细菌产物（如细菌素和肽）在治疗实体瘤方面具有独特的特性和优势，例如可以精确靶向肿瘤细胞、对肿瘤细胞具有选择性毒性、对正常细胞的副作用低、对多药耐药癌细胞具有毒性活性、可用作靶向递药载体并增强药物递送，因此利用细菌产物进行肿瘤治疗引起了极大的关注。此外，它们的体积小、分子量低，使得它们易于合成和修饰。此外，近年来，基因工程扩大了肽治疗实体瘤的治疗能力，从而克服了肽的缺点。本文主要综述了细菌肽和细菌素在治疗人类实体瘤方面的新进展。
